North America ultra-low temperature freezer market is anticipated to reach US$ 313.19 million in 2027 from US$ 220.25 million in 2019 – GlobeNewswire

August 24, 2020 13:05 ET | Source: ReportLinker

New York, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Ultra-Low Temperature Freezer Market to 2027 Regional Analysis and Forecasts by Type ; End User ; and, Country" - https://www.reportlinker.com/p05953821/?utm_source=GNW High costs associated with ultra-low temperature freezers, is likely to restrain the growth of the market in the coming years.

However, developments in the healthcare market are expected to have a positive impact on the growth of the North American ultra-low temperature freezer market in the coming years. Ultra-low temperature freezers are designed for storage of biological materials such as virus, bacteria, eukaryotic cells, blood, and semen. These freezers are used in blood banks, hospitals, epidemic prevention services, research institutes, and biomedical engineering facilities, among others. Blood and blood components perform numerous vital functions in the human body.Consequently, severe blood loss could result in life-threatening conditions such as hypovolemic/hemorrhagic shock, which require immediate blood transfusion to prevent organ failure and death.

Blood transfusion is also used as supportive therapy for surgery, chemotherapy, and stem cell and organ transplantation, as well as in the treatment of acute and chronic diseases caused by deficiencies or defects in plasma proteins or cellular blood components, to avoid complications such as life-threatening hemorrhage or improve quality of life by reducing anemia-related symptoms. As per the data provided by the WHO, anemia affects ~25% of the population, which accounts for 1.6 billion people worldwide; toddlers and children of preschool age have the highest prevalence of anemia at 47.4% of their population group. Moreover, the number of people with hemophilia in the US is estimated to be ~20,000 individuals. The worldwide incidence of hemophilia is not well known but estimated among more than 400,000 people as per the National Hemophilia Foundation. According to the American National Red Cross 2018 data findings, about 7,000 units of platelets and 10,000 units of plasma are required daily in the US, and about 21 million blood components are transfused each year in the US. The Singapore Red Cross Society needs ~120,000 units of blood every year to meet the transfusion needs of patients, which is equivalent to ~400 units of blood per day. The increasing demand for access to safe blood and blood components for transfusion has led to the manufacturing or development of various types of blood bank freezers, which has increased the adoption of ULT freezers for secure storage along with strict guidelines of the WHO for the storage of blood samples. Moreover, the country is witnessing the increasing number of COVID-19 cases.For instance, in the US, the number of cases has been increased to 614,246 with 26,064 reported deaths.

Additionally, Mexico and Canada cases are also growing.The US and Canada have witnessed a sudden rise in the number of cases in just few days, which has compelled the governments to shut down all the business in order to prevent the spread of the COVID-19.

However, Mexico is likely to be least affected due to less research and development activities in the biomedical industry. In terms of type, the upright ULT freezers segment accounted for the largest share of the North American ultra-low temperature freezer market in 2019 and is estimated to mark the highest CAGR in the market during the forecast period, owing to the factors such as easier to organize because of having shelves. Also, the convenience of use of upright freezers has led to its dominance during 2019 and is expected to witness similar trend over the coming years. Centers For Disease Control And Prevention (CDC), Food and Drug Administration (FDA), Biomedical Research Centers (BRCs), Society of Infectious and Tropical Diseases (SIMIT), and International Stem Cell Corporation (ISCO) are among the significant primary and secondary sources for ultra-low temperature freezer included in the report. Read the full report: https://www.reportlinker.com/p05953821/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Lyon, FRANCE

Formats available:

See the original post:
North America ultra-low temperature freezer market is anticipated to reach US$ 313.19 million in 2027 from US$ 220.25 million in 2019 - GlobeNewswire

Incysus Therapeutics Announces Name Change to IN8bio, Inc. – GlobeNewswire

August 24, 2020 07:00 ET | Source: IN8bio, Inc.

NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on delivering innovative gamma-delta () T cell immunotherapies for the treatment of cancer, today announced that it has changed its name to IN8bio, Inc. (IN8bio or the Company). The Companys new name reflects its novel approach to cell therapy, focused on the development of gamma-delta T cells for anti-cancer therapies. These powerful immune cells possess properties of both innate and adaptive immune cells and can serve as a functional bridge between the two systems to impact tumor killing.

IN8bio was founded to develop novel immunotherapies to treat cancer. Our new name, IN8bio, reflects that focus, commented William Ho, President, Chief Executive Officer and co-founder of IN8bio. As we continue to treat patients in our ongoing clinical programs, we are focused on delivering the next generation of innovative cancer therapies.

IN8bio is using autologous, allogeneic and genetically modified gamma-delta T cells to address the high unmet need in both solid and liquid tumors. IN8bio entered the clinic in 2020 with two Phase 1 clinical trials which are currently enrolling patients. In February 2020, IN8bio initiated enrollment in a Phase 1 clinical trial of gamma-delta T cell immunotherapy in leukemia patients undergoing allogeneic stem cell transplantation. That trial, the first clinical trial of an expanded and activated allogeneic gamma-delta T cell immunotherapy, is being conducted with its partners at the University of Kansas Cancer Center. Additionally, in February 2020, IN8bio initiated enrollment in a Phase 1 clinical trial of patients with newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly. This trial is being conducted at the ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham. IN8bios proprietary Drug Resistant Immunotherapy (DRI), which is being used in the glioblastoma trial, is the first genetically engineered gamma-delta T cell therapy to be administered to patients.

About IN8bio IN8bio is focused on delivering novel immunotherapies for the treatment of cancer. By using allogeneic and genetically modified gamma-delta () T cells, IN8bios technology addresses certain challenges that immunotherapies face targeting cold, low mutation cancers. IN8bios immuno-oncology programs include activated and gene-modified adoptive cellular therapies that are designed to protect cells from chemotherapy and may allow novel combinations of drugs to disrupt the tumor microenvironment and increase immunogenicity. IN8bios first clinical program is targeted to address leukemia in patients who are undergoing hematopoietic stem cell transplant (HSCT) and its second program is targeted to the treatment of newly diagnosed glioblastoma in combination with chemotherapy. For more information about the Company and its programs, visit http://www.IN8bio.com.

Forward Looking Statements Certain statements herein concerning the Companys future expectations, plans and prospects, including without limitation, the Companys current expectations regarding its business strategy, product candidates, and clinical development process and timing, constitute forward-looking statements. The use of words such as may, might, will, should, expect, plan, anticipate, believe, estimate, project, intend, future, potential, or continue, the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Companys control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Companys current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Companys reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.

Contact: IN8bio, Inc. William Ho, President & CEO who@IN8bio.com +1 646.600.6GDT info@IN8bio.com http://www.IN8bio.com

Follow this link:
Incysus Therapeutics Announces Name Change to IN8bio, Inc. - GlobeNewswire

Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy – Endpoints News

Salk Institute scientist and serial biotech entrepreneur Ron Evans showed new mouse work yesterday that could point to a long-sought holy grail for diabetes treatment.

The study, published in Nature,involved a new approach for islet cell transplant, a diabetes therapy where dysfunctional insulin-producing cells on the pancreas are replaced with functional ones. The treatment has been around for a while and new ones are in development, but theyve been hampered by the fact that patients will reject the cells unless they go on immuno-suppressive drugs.

But, working with iPSC stem cells and tricks from immunotherapy, Evans and his team developed what they called immune-evasive clusters of cells essentially mini pancreases. Placed into mice, these cells secreted proper amounts of insulin without coming under fire from immune cells, pointing the way toward a similar approach in humans.

Most type 1 diabetics are children and teenagers, Evans said in a statement. We hope that regenerative medicine in combination with immune shielding can make a real difference in the field by replacing damaged cells with lab-generated human islet-like cell clusters that produce normal amounts of insulin on demand.

Evans, who most recently co-founded and sold to Astellas the exercise-in-a-pill biotech Mitobridge, and his co-authors are hardly alone in this race. ViaCyte has received major backing from both private donors and the Juvenile Diabetes Research Foundation for their own stem cell-derived islet cell transplant. Flagship also launched Sigilon earlier this year with $80.3 million in Series B funding. With technology from Robert Langer, the company is developing polymers that can encase cells for transplant. A diabetes program is in the IND-enabling phase with Eli Lilly.

Four years ago, Evans and his team figured out how to make functional pancreatic beta cells for the first time, using a series of molecular switches to get them to not only produce insulin but do so in response to glucose, as normal cells do. But that still left questions about how to go from individual cells into pancreas-like clusters, and how to get those cells to avoid the immune system when transplanted.

To cluster the cells, Evans lab figured out that a protein involved in embryonic development called WNT4 could trigger the same molecular mechanisms that created the functional beta cells. Adding that protein led to the creation of 3-D clusters of cells similar to what would be seen in a humans. They called them human islet-like organoids, or HILOs.

To make those organoids, Evans and Eiji Yoshihara, a scientist in his lab, stole a trick from another field: immuno-oncology. Using short pulses of a protein called interferon gamma, Yoshihara got the cells to express PD-L1.

The PD-L1 had the opposite effect of the PD-L1 inhibitors used in cancer. Rather than making sure T cells saw a tumor, they made sure T cells didnt see the islet cells.

This is the first study to show that you can protect HILOs from the immune system without genetic manipulation, Michael Downes, an author on the paper, said. If we are able to develop this as a therapy, patients will not need to take immune-suppressing drugs.

Go here to read the rest:
Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy - Endpoints News

Research Roundup: Lasting Immunity to COVID-19 and More – BioSpace

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

Multiple Studies Suggest Lasting Immunity to COVID-19 After Infection

Although probably not enough time has passed to know definitively, several studies are now suggesting that even mild cases of COVID-19 stimulate lasting immune responses, not only in disease-fighting antibodies, but in B- and T-cells.

Things are really working as theyre supposed to, Deepta Bhattacharya, an immunologist at the University of Arizona, and an author of one of the studies, told The New York Times.

Its difficult, probably impossible, to predict how long those immune responses will last, but many of the researchers believe the results are promising for long-term protection.

This is exactly what you would hope for, Marion Pepper, an immunologist at the University of Washington and an author of a study currently being reviewed by the journal Nature. All the pieces are there to have a totally protective immune response.

Pepper notes that the protective effects cant be completely evaluated until there is proof that people exposed to the virus a second time can fight it off. But the data suggests the immune system is indeed able to fight resistance a second time. Some of this qualification comes from unconfirmed reports of people being reinfected by the virus.

Antibody responses are typically relatively short-lived, disappearing from the blood weeks or months after being produced. Generally, the majority of the B-cells that produce antibodies die off, too. But the body keeps some longer-lived B-cells that are able to manufacture virus-fighting antibodies should the immune system be triggered by re-exposure to the virus. Some stay in the bloodstream while others wait in the bone marrow where they manufacture small numbers of antibodies that can sometimes be observed years, even decades later. Several studies, some by Bhattacharya and Pepper, have identified antibodies at low levels in the blood months after people recovered from COVID-19.

The antibodies decline, but they settle in what looks like a stable nadir, Bhattacharya said. These have been observed about three months after symptoms show up. The response looks perfectly durable.

Additional studies, including one published in the journal Cell, have isolated T-cells from recovered patients that can attack SARS-CoV-2. In laboratory studies, the T-cells produced signals to fight the virus and cloned themselves in large numbers to fight the potential infection.

This is very promising, said Smita Iyer, an immunologist at the University of California, Davis, who was not involved in the new studies, but has researched immune responses to the novel coronavirus in rhesus macaques. This calls for some optimism about herd immunity, and potentially a vaccine.

It's still has not been definitely determined if milder cases of COVID-19 will lead to long-term or even medium-term immunity. There have been some studies that suggest it does not and some newer studies suggesting it does. Iyer notes that the recent paper indicates, You can still get durable immunity without suffering the consequences of infection.

This idea is reinforced by Eun-Hyung Lee, an immunologist at Emory University who was not involved in these studies. He told The New York Times, Yes, you do develop immunity to this virus, and good immunity to this virus. Thats the message we want to get out there.

Why Seasonal Flu Vaccines Only Last a Year

As most everyone knows, flu vaccines only last about a year. Some of this is related to viral mutations. But in fact, the actual immunity itself caused by the vaccine does not appear to last longer than a year, even though the flu vaccine increases the number of antibody-producing cells specific for the flu in the bone marrow. Researchers out of Emory Vaccine Center found that for most newly-generated plasma cell lineages, between 70 and 99% of the cells were gone after one year, but that the levels of antibody-secreting cells in blood correlated with long-term response in the bone marrow.

Gut Bacteria Can Help Immuno-Oncology Therapies

Researchers with the University of Calgary identified gut bacteria that help our immune system fight cancerous tumors. This also helped provide more information about why immunotherapy works in some cases, but not others. By combining immunotherapy with specific microbial therapy, they believe they can help the immune system and immunotherapy be more effective in treating three types of cancer: melanoma, bladder and colorectal cancers. They found that specific bacteria were essential for immunotherapy to work in colorectal cancer tumors in germ-free mice. The bacteria produced a small molecule called inosine that interacts directly with T-cells and together with immunotherapy.

An Online Calculator to Predict Stroke Risk

Scientists at the University of Virginia Health System developed an online tool that measures the severity of a patients metabolic syndrome, a mix of conditions that includes high blood pressure, abnormal cholesterol levels and excess body fat. With it, they can then predict the patients risk for ischemic stroke. The study discovered that stroke risk increased consistently with metabolic syndrome severity even in patients that did not have diabetes. The tool is available for free at https://metscalc.org/.

A Link Between Autism and Cholesterol

Researchers at Harvard Medical School, Massachusetts Institute of Technology (MIT) and Northwestern University identified a subtype of autism that is the result of a cluster of genes that regulate cholesterol metabolism and brain development. They believe this information can help design precision-targeted therapies for this specific type of autism and improve screening efforts for earlier diagnosis of autism. They analyzed the DNA from brain samples that they then confirmed with the medical records of autistic individuals. They found that children with autism and their parents had significant alterations in lipid blood. However, there is much more to be understood, emphasizing the complexity of autism, which is affected by a variety of genetic and environmental factors.

Researchers Grow First Functioning Mini Human Heart Model

Investigators with Michigan State University grew the first miniature human heart model in the laboratory that is complete with all primary heart cell types and a functioning structure of chambers and vascular tissue. They utilized induced pluripotent stem cells which were obtained from consenting adults and created a functional mini heart in a few weeks. The primary value was in giving them an unprecedented view into how a fetal heart develops.

In the lab, we are currently using heart organoids to model congenital heart diseasethe most common birth defect in humans affecting nearly 1% of the newborn population, said Aitor Aguirre, senior author and assistant professor of biomedical engineering at MSUs Institute for Quantitative Health Science and Engineering. With our heart organoids, we can study the origin of congenital heart disease and find ways to stop it.

Another area of focus is that improving on the final organoid will help with future research. Current heart organoids are not identical yet to human hearts and so are flawed in their use as research models.

More:
Research Roundup: Lasting Immunity to COVID-19 and More - BioSpace

The global market for Peripheral Blood Mononuclear Cells (PBMC) is projected to grow at a CAGR of around 9% during 2020 – 2025 – GlobeNewswire

August 21, 2020 13:04 ET | Source: ReportLinker

New York, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Peripheral Blood Mononuclear Cells Market, By Product, By Application, By Technique, By Source, By Region, Competition, Forecast & Opportunities, 2025" - https://www.reportlinker.com/p05953172/?utm_source=GNW

The global market for Peripheral Blood Mononuclear Cells (PBMC) is projected to grow at a CAGR of around 9% during 2020 - 2025.The PBMC are crucial to carry out the biology and pathology related studies as well as in clinical research.

Besides, PBMCs are also utilized in research related to fatal diseases, immunology, vaccine development, etc. However, high cost of PBMCs related studies might act as a challenge for the adoption of technology, especially in developing economies. The global peripheral blood mononuclear cells market is segmented based on product, application, technique, source, and region.The product segment is further divided into cryopreserved or frozen PBMC, cultured or fresh PBMC and peripheral blood mononuclear cell isolation & viability kits.

As of 2019, the cryopreserved PBMC or the frozen PBMC segment held the highest market share as they can be used for longer durations of time if stored carefully at lower temperatures.In terms of regional analysis, North America accounted for the largest market share in the year 2019, on the back of a number of pre-existing peripheral blood mononuclear cells-based companies in the region.

The economy of the region is also rich enough, which makes it easier to carry out the complex and costly R&D procedures. Major players operating in the global peripheral blood mononuclear cells market include Astarte Biologics, Inc., ATZLabs, BioIVT, BioLegend, Inc., BioVision, Bio-Rad, Cell Applications, Inc., Celgene, Creative Bioarray, Dapcel, Inc, HemaCare, iXCells Biotechnologies, Miltenyi Biotec, Merck, Novo Nordisk, Precision Medicine, Qiagen NV, STEMCELL Technologies Inc., Thermo Fisher Scientific, ZenBio, Inc., etc.

Years considered for this report:

Historical Years: 2015 - 2018 Base Year: 2019 Estimated Year: 2020 Forecast Period: 2021 - 2025

Objective of the Study:

To analyze and forecast the market size of global peripheral blood mononuclear cells market. To classify and forecast global peripheral blood mononuclear cells market based on product, application, technique, source, and region. To identify drivers and challenges for global peripheral blood mononuclear cells market. To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global peripheral blood mononuclear cells market. To conduct pricing analysis for global peripheral blood mononuclear cells market. To identify and analyze the profile of leading players operating in global peripheral blood mononuclear cells market. The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of leading market players across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the research organizations and companies which could not be identified due to the limitations of secondary research. The analyst examined the research organizations and companies, and presence of all major players across the globe. The analyst calculated the market size of global peripheral blood mononuclear cells market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Biotechnology and pharma companies and other stakeholders Government bodies such as regulating authorities and policy makers Organizations, forums and alliances related to peripheral blood mononuclear cells Market research and consulting firms The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as research organizations & companies and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global peripheral blood mononuclear cells market has been segmented into following categories, in addition to the industry trends which have also been detailed below: Market, By Product: o Cryopreserved or Frozen PBMC o Cultured or Fresh PBMC o Peripheral Blood Mononuclear Cell Isolation & Viability Kits Market, By Application: o Immunology o Infectious disease o Hematology o Others Market, By Technique: o Density gradient centrifugation process o Leukapheresis Market, By Source: o Human o Animals Market, By Region: o Asia-Pacific - China - India - Japan - South Korea - Singapore - Australia o Europe - France - Germany - United Kingdom - Italy o North America - United States - Mexico - Canada o South America - Brazil - Argentina - Colombia o Middle east & Africa - South Africa - Saudi Arabia - UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global peripheral blood mononuclear cells market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five). Read the full report: https://www.reportlinker.com/p05953172/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
The global market for Peripheral Blood Mononuclear Cells (PBMC) is projected to grow at a CAGR of around 9% during 2020 - 2025 - GlobeNewswire